Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen halts Vectibix combo trial

Executive Summary

In an interim analysis of the study PACCE, Amgen finds that patients receiving Vectibix (panitumumab) combined with Genentech's Avastin (bevacizumab) and standard chemotherapy for treatment of first-line metastatic colorectal cancer had less chance of survival than patients receiving Avastin and chemotherapy alone. The EGFR inhibitor received accelerated approval on the basis of demonstrated improvement in progression-free survival in September, but failed to show an effect on overall survival. Amgen is continuing Phase III trials of Vectibix as a single agent in combination with chemotherapy...

You may also be interested in...



Quick Listen: Scrip’s Five Must-Know Things

Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.

Prop 65 Warnings Intended For Small Spaces But Used On Luggage? California Proposes Limits

California proposes limiting short-form Prop 65 warnings to products with 5 inches or less of labeling space, while prohibiting their use in online and catalog warnings. The number of products with the warnings, used even on vacuum cleaners, luggage and guitars, has made tracking them impossible.

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

UsernamePublicRestriction

Register

ID1125791

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel